Notably, CTX130, an allogeneic CD70-targeted CAR-T cell therapy, demonstrated promising preclinical activity and early clinical efficacy in a phase I trial involving 16 patients with relapsed/refractory clear cell renal cell carcinoma (ccRCC). Here, CD70 is linked to clear cell renal carcinoma.